BiotechTube
Zena Therapeutics

Zena Therapeutics

Cambridge, United States· Est.
zenatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Zena Therapeutics is a private, preclinical biotech company founded in 2018 and based in Cambridge, USA. The company is developing a novel platform of GABA-A receptor PAMs with a ceiling effect on respiratory depression, aiming to create fast-acting anxiolytics with reduced abuse liability and fatal overdose risk. Its initial focus is on anxiety disorders and withdrawal-induced anxiety from opioid and alcohol use disorder. The company has secured over $1.7MM in non-dilutive grants and pre-seed funding to advance its lead candidate.

Mental HealthAddiction DisordersNeurological Disorders

Technology Platform

Novel class of GABA-A receptor positive allosteric modulators (PAMs) designed with a partial agonist profile to create a ceiling effect on respiratory depression, reducing overdose risk and abuse liability.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The company addresses a massive unmet need for safer anxiolytics, particularly for patients with substance use disorders who are currently contraindicated for existing treatments.
The growing public health focus on the opioid epidemic and mental health creates a favorable environment for funding and regulatory pathways for such therapies.

Risk Factors

High preclinical failure risk as the novel mechanism must prove safe and effective in human trials.
The company faces significant future capital requirements to fund clinical development and intense competition from larger pharma and other biotechs in the CNS space.

Competitive Landscape

Zena competes in the crowded CNS therapeutic space against large pharma companies with established benzodiazepines and SSRIs/SNRIs, as well as other biotechs developing novel neuromodulators (e.g., neurosteroids, psychedelics). Its key differentiation is the explicit design for a ceiling on respiratory depression, a direct attempt to solve the fatal flaw of current fast-acting anxiety treatments.

More companies in Small Molecule Drugs →More companies in United States →